Abstract
Recombinant adeno-associated virus (rAAV) vectors have revolutionized genetherapy, but their broad tropism and suboptimal transduction efficiency limittheir clinical applications. To overcome these limitations, researchers havefocused on designing and screening capsid libraries to identify improvedvectors. However, the large sequence space and limited resources presentchallenges in identifying viable capsid variants. In this study, we propose anend-to-end diffusion model to generate capsid sequences with enhancedviability. Using publicly available AAV2 data, we generated 38,000 diverse AAV2viral protein (VP) sequences, and evaluated 8,000 for viral selection. Theresults attested the superiority of our model compared to traditional methods.Additionally, in the absence of AAV9 capsid data, apart from one wild-typesequence, we used the same model to directly generate a number of viablesequences with up to 9 mutations. we transferred the remaining 30,000 samplesto the AAV9 domain. Furthermore, we conducted mutagenesis on AAV9 VPhypervariable regions VI and V, contributing to the continuous improvement ofthe AAV9 VP sequence. This research represents a significant advancement in thedesign and functional validation of rAAV vectors, offering innovative solutionsto enhance specificity and transduction efficiency in gene therapyapplications.